CDFI with spectral analysis has an advantage over the other two techniques in monitoring the efficacy of chemotherapy in bone sarcomas because of its superior accuracy, noninvasive nature, availability, and low cost.
No takes yet. Share an insight, caveat, or question.
Woude et al. (1994) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: